Product Specifications Active Compound: Retatrutide peptide Strength: 30mg per vial Form: Lyophilized powder Reconstitution Required: Yes, according to a validated laboratory protocol Manufacturer, as listed: Novera Compounds Country of Origin, as listed: United States Brand: Novera Intended Use: Laboratory and in vitro research only Package Content: 1 x 30mg vial Weight: 7 grams Dimensions: Width: 20mm | Height: 40mm | Length: 20mm Human-Use Status: Not approved for human use, clinical application, injection, or consumption Researchers should verify the product label, certificate of analysis, batch identity, purity method, storage requirements, safety data sheet, and manufacturer information before use
ClinicalTrials.gov ClinicalTrials.gov
Because of this, most fluctuations in HRV, particularly short-term time domain metrics like RMSSD, are best understood as reflecting changes in PNS tone such as vagal withdrawal during stress or vagal dominance at rest
Retatrutide (LY3437943) is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, currently without marketing authorisation from the MHRA or EMA
When your gut is already dealing with a GLP-1 medication, these sweeteners can amplify discomfort
however, gastrointestinal adverse effects such as nausea, vomiting, and diarrhea are the most frequently reported, particularly during the initial treatment phase (Wilding et al., 2021
